Overview News About Filings Financials Offerings
RGNT price & chart Provider market data
TradingView · Data may be delayed
About the company We are a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore the health and enhance the quality of life of patients. Our current efforts are focused on orthopedic treatments using our Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a unique hydrogel matrix of polyethylene glycol diacrylate (a polymer involved in tissue engineering) and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Our lead product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.
F-1 · 2026-07-08 · 0001213900-26-076392
Company description from the cited filing.
In the news No coverage from other publishers is available.
Seeking Alpha Seeking Alpha · 2026-06-18
SEC disclosures SEC · 2026-09-23
SEC · 2026-07-14
SEC · 2026-07-13
Financials FY 2025 · USD Revenue — · FY 2025 Net income -13,648,000 USD · FY 2025 Source 20-F · 2026-02-24 · 0001213900-26-019917
2025-01-01 to 2025-12-31
Assets 7,618,000 USD · FY 2025 Source 20-F · 2026-02-24 · 0001213900-26-019917
As of 2025-12-31
Cash 7,378,000 USD · FY 2025 Source 20-F · 2026-02-24 · 0001213900-26-019917
As of 2025-12-31
Operating income -6,968,000 USD · FY 2025 Source 20-F · 2026-02-24 · 0001213900-26-019917
2025-01-01 to 2025-12-31
Diluted EPS -24.16 USD per share · FY 2025 Source 20-F · 2026-02-24 · 0001213900-26-019917
2025-01-01 to 2025-12-31
Some figures are unavailable for this reporting year.
balance sheet · annual statements Line item FY 2025 FY 2024 ASSETS Assets USD 7,618,000Source 20-F · 2026-02-24 · 0001213900-26-019917
As of 2025-12-31
482,000Source 20-F · 2026-02-24 · 0001213900-26-019917
As of 2024-12-31
Current assets: Cash and Cash Equivalents, at Carrying ValueUSD 7,378,000Source 20-F · 2026-02-24 · 0001213900-26-019917
As of 2025-12-31
— LIABILITIES AND EQUITY Liabilities USD 2,874,000Source 20-F · 2026-02-24 · 0001213900-26-019917
As of 2025-12-31
6,488,000Source 20-F · 2026-02-24 · 0001213900-26-019917
As of 2024-12-31
Stockholders’ equity: Additional Paid in CapitalUSD 60,538,000Source 20-F · 2026-02-24 · 0001213900-26-019917
As of 2025-12-31
1,042,000Source 20-F · 2026-02-24 · 0001213900-26-019917
As of 2024-12-31
Retained Earnings (Accumulated Deficit)USD -55,794,000Source 20-F · 2026-02-24 · 0001213900-26-019917
As of 2025-12-31
-42,146,000Source 20-F · 2026-02-24 · 0001213900-26-019917
As of 2024-12-31
Stockholders' Equity Attributable to Parent USD 4,744,000Source 20-F · 2026-02-24 · 0001213900-26-019917
As of 2025-12-31
-41,104,000Source 20-F · 2026-02-24 · 0001213900-26-019917
As of 2024-12-31
Liabilities and Equity USD 7,618,000Source 20-F · 2026-02-24 · 0001213900-26-019917
As of 2025-12-31
482,000Source 20-F · 2026-02-24 · 0001213900-26-019917
As of 2024-12-31
Current liabilities: Liabilities, Current USD 2,874,000Source 20-F · 2026-02-24 · 0001213900-26-019917
As of 2025-12-31
6,488,000Source 20-F · 2026-02-24 · 0001213900-26-019917
As of 2024-12-31
Additional Financial Items Accrued Liabilities, CurrentUSD 1,393,000Source 20-F · 2026-02-24 · 0001213900-26-019917
As of 2025-12-31
1,127,000Source 20-F · 2026-02-24 · 0001213900-26-019917
As of 2024-12-31
Lines labelled “Derived” are calculated from reported figures.
cash flow · annual statements Line item FY 2025 FY 2024 Cash flows from operating activities: Adjustments to reconcile net income to net cash provided by operating activities: Share-based Payment Arrangement, Noncash ExpenseUSD 7,042,000Source 20-F · 2026-02-24 · 0001213900-26-019917
2025-01-01 to 2025-12-31
— Net Cash Provided by (Used in) Operating Activities USD -1,375,000Source 20-F · 2026-02-24 · 0001213900-26-019917
2025-01-01 to 2025-12-31
-641,000Source 20-F · 2026-02-24 · 0001213900-26-019917
2024-01-01 to 2024-12-31
Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities USD 8,524,000Source 20-F · 2026-02-24 · 0001213900-26-019917
2025-01-01 to 2025-12-31
525,000Source 20-F · 2026-02-24 · 0001213900-26-019917
2024-01-01 to 2024-12-31
Additional Financial Items Amortization of Debt Issuance CostsUSD — 115,000Source 20-F · 2026-02-24 · 0001213900-26-019917
2024-01-01 to 2024-12-31
Gain (Loss) on Extinguishment of DebtUSD — 68,000Source 20-F · 2026-02-24 · 0001213900-26-019917
2024-01-01 to 2024-12-31
General and Administrative ExpenseUSD 6,637,000Source 20-F · 2026-02-24 · 0001213900-26-019917
2025-01-01 to 2025-12-31
712,000Source 20-F · 2026-02-24 · 0001213900-26-019917
2024-01-01 to 2024-12-31
Net Income (Loss) Attributable to Parent USD -13,648,000Source 20-F · 2026-02-24 · 0001213900-26-019917
2025-01-01 to 2025-12-31
4,801,000Source 20-F · 2026-02-24 · 0001213900-26-019917
2024-01-01 to 2024-12-31
Nonoperating Income (Expense)USD -6,680,000Source 20-F · 2026-02-24 · 0001213900-26-019917
2025-01-01 to 2025-12-31
3,869,000Source 20-F · 2026-02-24 · 0001213900-26-019917
2024-01-01 to 2024-12-31
Other Nonoperating Income (Expense)USD -1,904,000Source 20-F · 2026-02-24 · 0001213900-26-019917
2025-01-01 to 2025-12-31
-77,000Source 20-F · 2026-02-24 · 0001213900-26-019917
2024-01-01 to 2024-12-31
Lines labelled “Derived” are calculated from reported figures.
income statement · annual statements Line item FY 2025 FY 2024 Operating Income (Loss) USD -6,968,000Source 20-F · 2026-02-24 · 0001213900-26-019917
2025-01-01 to 2025-12-31
932,000Source 20-F · 2026-02-24 · 0001213900-26-019917
2024-01-01 to 2024-12-31
Other Nonoperating Income (Expense)USD -1,904,000Source 20-F · 2026-02-24 · 0001213900-26-019917
2025-01-01 to 2025-12-31
-77,000Source 20-F · 2026-02-24 · 0001213900-26-019917
2024-01-01 to 2024-12-31
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest USD 13,648,000Source 20-F · 2026-02-24 · 0001213900-26-019917
2025-01-01 to 2025-12-31
-4,801,000Source 20-F · 2026-02-24 · 0001213900-26-019917
2024-01-01 to 2024-12-31
Net Income (Loss) Attributable to Parent USD -13,648,000Source 20-F · 2026-02-24 · 0001213900-26-019917
2025-01-01 to 2025-12-31
4,801,000Source 20-F · 2026-02-24 · 0001213900-26-019917
2024-01-01 to 2024-12-31
Earnings Per Share, BasicUSD per share -24.16Source 20-F · 2026-02-24 · 0001213900-26-019917
2025-01-01 to 2025-12-31
1.72Source 20-F · 2026-02-24 · 0001213900-26-019917
2024-01-01 to 2024-12-31
Earnings Per Share, DilutedUSD per share -24.16Source 20-F · 2026-02-24 · 0001213900-26-019917
2025-01-01 to 2025-12-31
1.72Source 20-F · 2026-02-24 · 0001213900-26-019917
2024-01-01 to 2024-12-31
Weighted Average Number of Shares Outstanding, Basicshares 566,744Source 20-F · 2026-02-24 · 0001213900-26-019917
2025-01-01 to 2025-12-31
2,765,850Source 20-F · 2026-02-24 · 0001213900-26-019917
2024-01-01 to 2024-12-31
Weighted Average Number of Shares Outstanding, Diluted shares 566,744Source 20-F · 2026-02-24 · 0001213900-26-019917
2025-01-01 to 2025-12-31
2,765,850Source 20-F · 2026-02-24 · 0001213900-26-019917
2024-01-01 to 2024-12-31
Additional Financial Items General and Administrative ExpenseUSD 6,637,000Source 20-F · 2026-02-24 · 0001213900-26-019917
2025-01-01 to 2025-12-31
712,000Source 20-F · 2026-02-24 · 0001213900-26-019917
2024-01-01 to 2024-12-31
Interest Expense, DebtUSD 79,000Source 20-F · 2026-02-24 · 0001213900-26-019917
2025-01-01 to 2025-12-31
10,000Source 20-F · 2026-02-24 · 0001213900-26-019917
2024-01-01 to 2024-12-31
Nonoperating Income (Expense)USD -6,680,000Source 20-F · 2026-02-24 · 0001213900-26-019917
2025-01-01 to 2025-12-31
3,869,000Source 20-F · 2026-02-24 · 0001213900-26-019917
2024-01-01 to 2024-12-31
Other ExpensesUSD 60,000Source 20-F · 2026-02-24 · 0001213900-26-019917
2025-01-01 to 2025-12-31
60,000Source 20-F · 2026-02-24 · 0001213900-26-019917
2024-01-01 to 2024-12-31
Lines labelled “Derived” are calculated from reported figures.
Offerings Registration 333-297320 F-1 · 2026-07-08 · 0001213900-26-076392
Terms from the governing filing for this registration; not a claim that the offering is open today.
Registration 333-295510 F-1/A · 2026-06-09 · 0001213900-26-066555
Terms from the governing filing for this registration; not a claim that the offering is open today.